

## Product datasheet for **TP727795**

### Angptl3 Mouse Recombinant Protein

#### Product data:

|                                       |  |
|---------------------------------------|--|
| Product Type:                         | Recombinant Proteins   |
| Description:                          | Recombinant Mouse Angiopoietin-related Protein 3/ANGPTL3 (Ser17-Thr206)(C-6His)  |
| Species:                              | Mouse  |
| Expression cDNA Clone or AA Sequence: | Ser17-Thr206   |
| Tag:                                  | C-His  |
| Buffer:                               | Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4.  |
| Note:                                 | Recombinant Mouse Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Thr206 is expressed with a 6His tag at the C-terminus.  |
| Storage:                              | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.  |
| Stability:                            | 12 months from date of despatch  |
| Locus ID:                             | 30924  |
| UniProt ID:                           | <a href="#">Q9R182</a>   |
| Synonyms:                             | Angiopoietin-related Protein 3; Angiopoietin-like protein 3; Angptl3   |
| Summary:                              | Angiopoietin-like Protein 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature mouse ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids. This activity requires a putative heparin-binding motif which is N-terminal to the coiled coil domain. Proteolytic removal of the fibrinogen-like domain from the N-terminal fragment serves to activate ANGPTL3 and increase its ability to inhibit LPL in vitro and function in vivo. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TRÎ² or PPARÎ². ANGPTL3, secreted by fetal liver cells, also promotes the expansion of hematopoietic stem cells. |


[View online »](#)